TSS
LCTX icon

Two Sigma Securities’s Lineage Cell Therapeutics LCTX Stock Holding History

Two Sigma Securities’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.2K Sell
20,390
-3,208
-14% -$5.41K ﹤0.01% 1317
2025
Q4 		$39.4K Buy
+23,598
New +$40.8K 0.01% 1106
2025
Q3 		– Sell
-18,028
Closed -$16.4K – 1746
2025
Q2 		$16.4K Buy
+18,028
New +$10.7K ﹤0.01% 1241
2024
Q4 		– Sell
-13,941
Closed -$12.6K – 2496
2024
Q3 		$12.6K Buy
+13,941
New +$12.9K ﹤0.01% 2557
2024
Q1 		– Sell
-12,704
Closed -$13.8K – 3315
2023
Q4 		$13.8K Buy
+12,704
New +$13.9K ﹤0.01% 2778
2023
Q2 		– Sell
-16,538
Closed -$24.8K – 3100
2023
Q1 		$24.8K Sell
16,538
-782
-5% -$1.09K ﹤0.01% 2336
2022
Q4 		$20.3K Buy
+17,320
New +$21.8K ﹤0.01% 2278
2021
Q4 		– Sell
-96,762
Closed -$244K – 1815
2021
Q3 		$244K Buy
+96,762
New +$248K 0.01% 1116
2018
Q4 		– Sell
-14,906
Closed -$31K – 2527
2018
Q3 		$31K Buy
+14,906
New +$31.3K ﹤0.01% 2394

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Securities's LCTX Position: Q1 2026 in Review

Two Sigma Securities reduced its Lineage Cell Therapeutics (LCTX) stake by 14% in Q1 2026, selling an estimated $5.41K and leaving 20,390 shares worth $32.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1317.

Two Sigma Securities first reported a position in LCTX in Q3 2018 and has held it in 9 quarters since. The position peaked at $244K in Q3 2021. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • Two Sigma Securities held 20,390 shares of Lineage Cell Therapeutics worth $32.2K as of Q1 2026.
  • Two Sigma Securities sold 3,208 Lineage Cell Therapeutics shares in Q1 2026, an estimated $5.41K.
  • Lineage Cell Therapeutics made up ﹤0.01% of Two Sigma Securities's portfolio in Q1 2026, its #1317 holding.
  • Two Sigma Securities first reported a position in Lineage Cell Therapeutics in Q3 2018 and has held it in 9 quarters since.
  • Two Sigma Securities's Lineage Cell Therapeutics position peaked at $244K in Q3 2021.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.